Skip to main content
Epidermolysis BullosaRare diseaseChildren's healthBiologicalPhase 1, Phase 2

What this study is

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum.

Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

What's being tested

  • Immunoglobulin G

    Intervention · BIOLOGICAL

    Purified IgG from human serum, delivered via IV

Study details

Sponsor
M. Peter Marinkovich
Conditions
Epidermolysis Bullosa · Epidermolysis Bullosa Acquisita · Dystrophic Epidermolysis Bullosa · Recessive Dystrophic Epidermolysis Bullosa
Enrolling
8 people
Starts
2025-08-04
Est. completion
2027-03
Design
Open-label, single group, Phase 1, Phase 2
Record
View on ClinicalTrials.gov ↗